Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy

Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

(2020) Thomas Yau et al.   JOURNAL OF CLINICAL ONCOLOGY

A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy

(2020) Masatoshi Kudo   Liver Cancer

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?

(2020) Nadiya Hussain et al.   Human Vaccines & Immunotherapeutics

Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade

(2020) David J. Pinato et al.   Cancers

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications

(2019) Biagio Ricciuti et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer

(2019) David J. Pinato et al.   JAMA Oncology

Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario

(2019) Giovanni Rossi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

(2018) Peter R. Galle et al.   JOURNAL OF HEPATOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC

(2018) Fernando Costa Santini et al.   Cancer Immunology Research

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy

(2018) Amber J. Giles et al.   Journal for ImmunoTherapy of Cancer

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma

(2018) Michael J Flynn et al.   HEPATOLOGY

The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma

(2017) David J. Pinato et al.   JOURNAL OF HEPATOLOGY

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Corticosteroids for Anorexia in Palliative Medicine: A Systematic Review

(2014) Sarah Miller et al.   JOURNAL OF PALLIATIVE MEDICINE

How Steroids Steer T Cells

(2014) Claude Libert et al.   Cell Reports